Welcome to our dedicated page for Cytosorbents SEC filings (Ticker: CTSO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a medical-device firm’s disclosures can feel like a lab manual. CytoSorbents� filings pack clinical-trial data, FDA feedback, and grant accounting into hundreds of pages—just when you need quick answers. If you have ever searched for “CytoSorbents SEC filings explained simply,� this page is your direct route to clarity.
Stock Titan applies AI to every document the moment it hits EDGAR. That means you can open a CytoSorbents quarterly earnings report 10-Q filing and see cash-burn highlights in seconds, or scan CytoSorbents Form 4 insider transactions real-time to spot when executives adjust their stakes. Whether you are comparing R&D spend across quarters or decoding an 8-K about a new FDA IDE, our summaries turn technical language into actionable insight.
Below you will find every form, updated the instant it’s published, along with context on why it matters:
- CytoSorbents insider trading Form 4 transactions � follow buying or selling linked to clinical milestones.
- CytoSorbents earnings report filing analysis � AI pulls revenue from EU sales, grant income, and trial costs.
- CytoSorbents annual report 10-K simplified � understand polymer-adsorption technology, patents, and risk factors without wading through 300 pages.
- CytoSorbents proxy statement executive compensation � see how incentive plans align with pivotal study outcomes.
- CytoSorbents executive stock transactions Form 4 � track patterns ahead of material announcements.
- CytoSorbents 8-K material events explained � instant context on trial results, CE-Mark renewals, or government contracts.
- Guides for understanding CytoSorbents SEC documents with AI, including glossaries and metric trackers.
From real-time alerts to plain-language briefs, Stock Titan equips you to act on new information faster than anyone still scrolling through PDFs.
MGIC Investment Corp. (MTG) � Form 4 insider transaction
President & COO Salvatore A. Miosi disclosed the sale of 30,000 shares of common stock on 01-Jul-2025 at a weighted-average price of $28.152 per share, generating roughly $0.84 million in proceeds. The disposition was executed under a Rule 10b5-1 trading plan adopted on 06-Mar-2025, indicating the sale was pre-scheduled and not necessarily driven by near-term information.
After the transaction, Miosi directly owns 279,401.361 shares and indirectly controls 384,844 shares via a family trust, maintaining a sizable equity stake. No derivative security activity was reported, and the filing contains no references to earnings, major corporate events, or strategic changes.
The filing primarily records a routine adjustment to the executive’s equity exposure; in isolation, it is unlikely to materially affect the company’s fundamental outlook.
CytoSorbents Corporation (Nasdaq: CTSO) filed a Form 8-K on June 24, 2025 to disclose a material regulatory development. Under Item 8.01 � Other Events, the company reported that it has decided to appeal the U.S. Food & Drug Administration’s (FDA) denial letter related to its De Novo request for DrugSorb-ATR, a blood purification device designed to remove antithrombotic agents during cardiothoracic surgery. The filing furnishes a press release (Exhibit 99.1) as additional detail; however, that release is not included in the body of the 8-K.
The appeal process indicates that management believes there are sufficient grounds to contest the FDA’s decision, but the 8-K offers no timetable, data, or probability of success. No sales, earnings, or forecast information is provided, and no other corporate actions (financing, partnerships, leadership changes) are mentioned. Investors should note that DrugSorb-ATR represents an important U.S. commercial opportunity for CTSO, but the denial—now under appeal—introduces regulatory uncertainty and potential delays to market entry.